The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Access Pharmaceuticals Inc.  (ACCP) Trade Now »     Rate ACCP  -  Discuss ACCP  -  Add to Watch List         Graphic_subscribe

  
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate ACCP:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

ACCP: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Access Pharma (OTC: ACCP.OB): MuGard Launch Expected 1Q10 Graphic_rating_buy ACCP
Mikerun
73%
 
Access Pharma (OTC: ACCP.OB) provided an update today on the status of the North American commercial launch for its FDA cleared treatment for oral mucositis, MuGard, which is expected to occur during 1Q10 in conjunction with the availability of initial product inventory by its liquid contract manufacturing partner, Accupac. In addition, Access signed an e-Marketing deal with iMedicor (OTC: VMCI.OB) in early October as a cost-efficient and highly targeted means of reaching over 200,000 oncologists in the U.S. market.
 
<> The e-Marketing deal and pending domestic MuGar...
By  Mike Havrilla   (+1.04%  risk: conservative)  11/11/09 Comment


FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving? Graphic_rating_buy ACCP
Mikerun
73%
<> <> On 7/15/09, Cadence Pharma (NASDAQ: CADX) announced that its New Drug Application (NDA) for Acetavance (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the FDA and designated for a priority (six-month) review. The FDA has issued a PDUFA action date for the NDA of 11/13/09 for a possible decision by the Agency. The Company's 505(b)(2) NDA for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and ...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/25/09 Comment


Access Pharma (OTC: ACCP.OB): Clinical, Commercial MuGard Updates Graphic_rating_buy ACCP
Mikerun
73%
Access Pharma (OTC: ACCP.OB) provided an update this morning on the clinical and commercial status of MuGard, which has already been launched by its partner, SpePharm, in five European countries for the prevention and treatment of oral mucositis. SpePharm is currently collecting information from approximately 1,500-2,000 patients as part of a comprehensive set of post-marketing / seeding studies being conducted in the UK, Germany, and Italy. <o:p> </o:p>

<o:p>   </o:p>

http://www.mikehavrx.com/2009/10/access-pharma-otc-accpob-cli... <o:p> </o:p>

<> <> <o:p> ...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/15/09 Comment


Access Pharma, iMedicor Sign e-Marketing Deal for MuGard Graphic_rating_buy ACCP
Mikerun
73%
Access Pharma (OTC: ACCP.OB) announced an e-Marketing deal today with iMedicor (OTC: VMCI.OB) for the commercial launch of MuGard through the latter’s targeted marketing / education Alerts System application through NaviNet, which is a secure network of over 700,000 healthcare providers and support staff. Over 200,000 oncology-related clinicians in the U.S. will be targeted with information on MuGard and the treatment of oral mucositis, with an expected commercial launch before year-end.
 
<> <> <font> http://www.mikehavrx.com/2009/10/access-pharma-imedicor-sign-... </font>...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/06/09 Comment


Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities Graphic_rating_buy ACCP
Mikerun
73%
Access Pharma (OTC: ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining). <o:p> </o:p>

<o:p>   </o:p>

http://www.mikehavrx.com/2009/09/access-pharma-otc-accpob-mug... <o:p> </o:p>

<o:p>   </o:p>

<> <> In addition, the Company is devel...
By  Mike Havrilla   (+1.04%  risk: conservative)  09/29/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
NVDA NVIDIA Corp
DELL Dell Inc
YHOO Yahoo! Inc
PFE Pfizer Inc
FRE Freddie Mac
MSFT Microsoft Corp

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on ACCP

Visit streetinsider.com


Discussion Wall + Add  
Michael Vlaicu   (-0.27%  risk: conservative)
Conference Call – (OTC:ACCP) Access Pharmaceutica.. - StocksHaven Investments Access Pharmaceuticals Inc. (OTC:ACCP) At approximately 5:00pm EST, 6/23/09, StocksHaven Investments began the call co...
+   0 replies


More Resources

Graphic_arrow1 About Access Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch